Eleven Biotheraputics up 15% post-IPO

Eleven Biotherapeutics (EBIO) priced its 5M-share IPO at $10, opened at $10.35, and is currently trading at $11.50, up 15%.

The eye disease drug developer has a market cap of $177M.

Prospectus, IPO preview

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs